OR8S1 Antibody

What is OR8S1 and what is its biological function?

OR8S1 (Olfactory Receptor Family 8 Subfamily S Member 1) is a G-protein-coupled receptor involved in olfactory signal transduction. This protein belongs to the largest gene family in the human genome and functions primarily in the detection and discrimination of odor molecules. OR8S1 has a molecular weight of approximately 39-40 kDa and contains multiple transmembrane domains characteristic of olfactory receptors. While primarily expressed in olfactory sensory neurons, recent research has identified potential expression in non-olfactory tissues, suggesting possible additional functions beyond odorant detection .

What types of OR8S1 antibodies are currently available for research?

The predominant type available is rabbit polyclonal antibody against human OR8S1. These antibodies are typically generated using synthetic peptides derived from specific regions of the human OR8S1 protein, commonly the amino acid range 90-139 or the C-terminal region. Most commercially available options are unconjugated (not linked to reporter molecules) and purified through affinity chromatography using epitope-specific immunogens to enhance specificity . Different antibodies may target different epitopes, which can affect their performance in various experimental contexts and applications.

What are the recommended applications for OR8S1 antibodies?

OR8S1 antibodies have been validated for several research applications with specific recommended dilutions:

These applications allow researchers to detect OR8S1 protein in various experimental contexts, from protein extracts to fixed tissue sections . Optimization of these dilutions may be necessary depending on specific experimental conditions, sample types, and individual antibody characteristics.

How should Western blot protocols be optimized for OR8S1 detection?

Western blot detection of OR8S1 requires careful optimization due to its membrane protein nature and potential expression level challenges. For optimal results:

• Sample preparation: Use membrane protein extraction buffers containing appropriate detergents (1-2% Triton X-100, NP-40, or CHAPS) with complete protease inhibitor cocktails to prevent degradation.

• Protein loading: Load 30-50 μg of total protein per lane for cell lysates, potentially more for tissues with lower OR8S1 expression.

• Gel separation: Use 10-12% SDS-PAGE gels for optimal separation around the 39-40 kDa range.

• Transfer conditions: For this weight range, a semi-dry transfer at 15V for 30 minutes or wet transfer at 100V for 1 hour typically provides efficient transfer.

• Blocking: Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody: Dilute OR8S1 antibody 1:500-1:1000 in blocking buffer and incubate overnight at 4°C .

• Washing: Perform 4-5 washes with TBST, 5-10 minutes each.

• Secondary antibody: Use appropriate HRP-conjugated anti-rabbit secondary antibody at 1:5000-1:10000 dilution.

• Controls: Include a blocking peptide competition control when possible to confirm specificity of the observed band .

What are effective tissue preparation methods for immunohistochemical detection of OR8S1?

For optimal immunohistochemical detection of OR8S1 in tissue samples:

• Fixation: Use 10% neutral-buffered formalin for 24-48 hours, avoiding overfixation which can mask epitopes.

• Processing: Dehydrate, clear, and infiltrate with paraffin using standard protocols.

• Sectioning: Cut 4-6 μm thick sections and mount on positively charged slides.

• Antigen retrieval: Perform heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0), as membrane proteins often require robust antigen retrieval.

• Blocking: Block endogenous peroxidase with 3% H₂O₂ and non-specific binding with 5% normal serum or BSA.

• Primary antibody: Apply OR8S1 antibody at 1:50-1:200 dilution and incubate overnight at 4°C .

• Detection system: Use a sensitive detection system such as polymer-based HRP detection or tyramide signal amplification (TSA) for lower expression tissues.

• Counterstaining: Use hematoxylin for nuclear counterstaining, avoiding overstaining which can obscure membrane staining.

• Controls: Include both positive controls (known OR8S1-expressing tissues) and negative controls (primary antibody omission and isotype controls) .

How can researchers verify the specificity of an OR8S1 antibody?

Confirming antibody specificity is critical for reliable research outcomes. For OR8S1 antibodies, employ these methodological approaches:

• Blocking peptide competition: Pre-incubate the antibody with excess immunizing peptide before application to samples. Disappearance of the specific signal confirms antibody specificity .

• Molecular weight verification: In Western blots, confirm detection of a band at the expected molecular weight of 39-40 kDa.

• Knockout/knockdown validation: Compare samples from OR8S1 knockout models or siRNA-mediated knockdown cells with wild-type controls. A specific antibody will show reduced or absent signal in knockout/knockdown samples.

• Multiple antibody validation: Use multiple antibodies targeting different epitopes of OR8S1 and compare staining patterns.

• Recombinant expression: Overexpress tagged OR8S1 in a cell line and confirm detection with both the OR8S1 antibody and an antibody against the tag.

• Cross-reactivity testing: Test the antibody on tissues or cells known to express or not express OR8S1 to establish positive and negative controls .

• Protein array testing: Some manufacturers report validation by protein array testing against the target protein plus numerous non-specific proteins to ensure specificity .

What are the challenges in detecting OR8S1 in different experimental contexts?

Detecting OR8S1 presents several technical challenges that researchers should address methodologically:

• Low expression levels: Olfactory receptors often show low expression levels, particularly in non-olfactory tissues.

  • Solution: Use signal amplification systems (e.g., TSA) for IHC/IF or highly sensitive ECL substrates for Western blots.

• Membrane protein extraction: As a G-protein coupled receptor, OR8S1 has multiple transmembrane domains that complicate extraction.

  • Solution: Use specialized membrane protein extraction buffers containing appropriate detergents to efficiently solubilize the protein without disrupting antibody-binding epitopes .

• Post-translational modifications: Potential glycosylation or phosphorylation may affect antibody recognition.

  • Solution: Consider using deglycosylation enzymes or phosphatase treatments before immunodetection.

• Fixation sensitivity: Some epitopes may be masked during fixation procedures.

  • Solution: Compare multiple fixation methods and optimize antigen retrieval procedures .

• Cross-reactivity: The high sequence similarity among olfactory receptor family members can complicate specific detection.

  • Solution: Use multiple antibodies targeting different epitopes and validate with genetic approaches.

How should researchers interpret contradictory results when using OR8S1 antibodies?

When encountering contradictory results with OR8S1 antibodies, a systematic approach to reconciling these discrepancies includes:

• Antibody source comparison: Different antibodies may target different epitopes with varying accessibility.

  • Solution: Test multiple antibodies targeting distinct regions of OR8S1 and compare results .

• Experimental condition variations: Buffer compositions, incubation times, and temperatures significantly affect antibody performance.

  • Solution: Standardize protocols across experiments and document all variables.

• Tissue/sample preparation differences: Fixation methods, antigen retrieval techniques, and protein extraction protocols impact epitope availability.

  • Solution: Perform parallel experiments with standardized sample preparation methods.

• Expression level threshold detection: Different detection methods have varying sensitivity thresholds.

  • Solution: Use quantitative methods alongside qualitative approaches.

• Methodological validation: Confirm antibody specificity using:

  • Blocking peptide competition assays

  • siRNA knockdown or CRISPR knockout controls

  • Heterologous expression systems with tagged OR8S1

• Data integration: Combine multiple methodologies (WB, IHC, IF) to build a comprehensive understanding.

What is known about OR8S1 expression patterns in human tissues?

OR8S1 expression patterns are primarily associated with olfactory epithelium, but research data indicates:

For comprehensive tissue distribution studies, researchers should:

• Use multiple detection methods (IHC, WB, and qPCR)

• Include appropriate positive and negative controls

• Consider developmental and physiological state variations in expression levels

• Validate findings with multiple antibodies targeting different epitopes

What are common issues when working with OR8S1 antibodies and how can they be resolved?

Researchers often encounter several challenges when working with OR8S1 antibodies. Here are methodological solutions to common issues:

• Issue: Weak or no signal in Western blot
  Solutions:

  • Increase protein loading (50-100 μg total protein)

  • Optimize antibody concentration (try 1:250-1:500 dilution)

  • Extend primary antibody incubation to overnight at 4°C

  • Use a more sensitive detection system

  • Try alternative extraction buffers specifically designed for membrane proteins

• Issue: High background in immunohistochemistry/immunofluorescence
  Solutions:

  • Increase blocking time (2-3 hours) or concentration (5% BSA or normal serum)

  • Add 0.1-0.3% Triton X-100 to antibody diluent

  • Extend washing steps (5 washes of 10 minutes each)

  • Reduce primary antibody concentration

  • Use a different secondary antibody with less cross-reactivity

• Issue: Multiple bands in Western blot
  Solutions:

  • Use fresher samples with complete protease inhibitors

  • Try different lysis buffers to improve protein extraction

  • Perform peptide competition assay to identify the specific band

  • Run gradient gels for better separation

• Issue: Variable results between experiments
  Solutions:

  • Standardize all protocols, reagents, and incubation times

  • Prepare larger batches of antibody dilutions for consistency

  • Include positive controls in every experiment

  • Use the same lot number of antibody when possible

What controls should be used when working with OR8S1 antibodies?

Rigorous experimental design requires appropriate controls to ensure reliable results when working with OR8S1 antibodies:

• Positive controls:

  • Tissues or cell lines with confirmed OR8S1 expression (e.g., olfactory epithelium, HT-29 cells)

  • Recombinant OR8S1 protein or cells transfected with OR8S1 expression constructs

  • Synthetic peptide corresponding to the immunogen

• Negative controls:

  • Tissues or cell lines with confirmed absence of OR8S1 expression

  • OR8S1 knockout or knockdown samples

  • Secondary antibody only control (omitting primary antibody)

  • Isotype control (using non-specific IgG from same species as primary antibody)

• Specificity controls:

  • Peptide competition/blocking experiments using the immunizing peptide

  • Pre-absorption controls with related proteins to assess cross-reactivity

  • Multiple antibodies targeting different epitopes of OR8S1

• Technical controls:

  • Loading controls for Western blot (e.g., β-actin, GAPDH)

  • Internal staining controls for IHC/IF (tissues with known expression patterns)

  • Dilution series of primary antibody to determine optimal concentration

Implementation of these comprehensive controls strengthens the validity of research findings and facilitates troubleshooting when unexpected results occur.